Hepatitis C Virus Treatments

For recommended and alternative regimens for specific patient populations (eg, treatment-experienced patients previously treated with regimens other than PEG-IFN/ribavirin, decompensated cirrhosis, HIV/HCV co-infection, renal impairment, etc), refer to the full guideline or drug manufacturer’s labeling.

¹ Patients with no baseline NS5A RASs for elbasvir detected. Includes G1a substitutions at amino acid positions 28, 30, 31, or 93.

² An 8-week duration is recommended for treatment-naïve patients without cirrhosis who are non-black, HIV uninfected, and whose HCV RNA level is <6 million IU/ml.

³ Patients who have baseline NS5A RASs for elbasvir. Includes G1a substitutions at amino acid positions 28, 30, 31, or 93.

⁴ Reference FDA warning regarding use of ombitasvir/paritaprevir/ritonavir +/− dasabuvir in patients with cirrhosis (risk of hepatic decompensation/hepatic failure).

⁵ Patients in whom no Q80K substitution is detected.

⁶ Alternative only for patients who are negative for the Q80K substitution by commercially available resistance assay. Other recommended or alternative regimens should be used for patients with genotype 1a compensated cirrhosis in whom the Q80K substitution is present.

⁷ Baseline RAS testing for Y93H is recommended. Ribavirin should be included in regimen or consider Vosevi if present.

⁸ 12 weeks is recommended for patients who experience virologic relapse after PEG-IFN/ribavirin therapy. Patients with prior on-treatment virologic failure (failure to suppress or breakthrough) while on PEG-IFN/ribavirin should be treated with 16 weeks and have weight-based ribavirin added.

⁹ For patients ineligible for ribavirin.

¹⁰ Strong inhibitors (eg, clarithromycin, itraconazole, ketoconazole, ritonavir, nefazodone).

¹¹ Strong inducers (eg, bosentan, dexamethasone, efavirenz, etravirine, modafinil, nafcillin, rifapentine, nevirapine).